RxDoctor Payments Data

Tina Higgins

Women's Health · Gulf Shores, ALNPI 1396259768

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novo Nordisk at 31.2% of the total. Reporting peaked in 2021 at $361 and has fallen 72.2% since, to $100 in 2025.

$938in general payments, 2019–2025

Across 26 payments — averaging $36.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$293
  • Mayne Pharma Commercial LLC$229
  • AbbVie$210
  • Lilly USA, LLC$39
  • Millicent US Inc$24
  • Bayer$20
  • plus $123 from 9 others

What the payments were for

  • Food & beverage$938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$938 in reported general payments places this provider in the 65th percentile of 107 women's health providers in Alabama.

See all women's health providers in Alabama

Medicare billing

Part B allowed, 2024
$7,492
Medicare patients
58
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$23,654
OzempicSemaglutide14$13,446
Estradiol136$3,732
ProgesteroneProgesterone, Micronized54$2,045
Estradiol (Twice Weekly)Estradiol20$1,026
Clobetasol Propionate20$692
Fluconazole42$576
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$372
Levothyroxine Sodium13$53
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)12$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$39$23,65422 claims
Novo NordiskOzempic$293$13,44614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 107 women's health providers in Alabama.

Other women's health in Gulf Shores

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →